
非小細胞肺がん
論文紹介
医師注目
次世代ALK阻害薬ensartinib、クリゾチニブ耐性のALK陽性NSCLCを対象とした多施設共同第Ⅱ相試験【Lancet Respir Med】
Ensartinib has activity and is well tolerated in patients with crizotinib-refractory,
ALK-positive NSCLC, including those with brain metastases. The role of ensartinib
in patients in whom other second-generation ALK inhibitors have been unsuccessful
warrants further studies.